SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-003664
Filing Date
2021-01-13
Accepted
2021-01-13 07:43:01
Documents
14
Period of Report
2021-01-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm213018d1_8k.htm   iXBRL 8-K 24843
2 EXHIBIT 99.1 tm213018d1_ex99-1.htm EX-99.1 12008
3 GRAPHIC image_001.jpg GRAPHIC 3247
  Complete submission text file 0001104659-21-003664.txt   219926

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20210113.xsd EX-101.SCH 3190
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20210113_lab.xml EX-101.LAB 34592
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20210113_pre.xml EX-101.PRE 22713
7 EXTRACTED XBRL INSTANCE DOCUMENT tm213018d1_8k_htm.xml XML 3615
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 21525079
SIC: 2834 Pharmaceutical Preparations